Triodent Meditech India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 17 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.20 M
- Revenue Growth -18.75%
- Profit Growth 5.38%
- Ebitda 8.44%
- Net Worth 7.64%
- Total Assets 48.36%
About Triodent Meditech India
Triodent Meditech India Private Limited (TMIPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 October 2007 and has a history of 17 years and three months. Its registered office is in Delhi, India.
The Company is engaged in the E-Commerce Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.20 M.
Brajesh Mishra and Rajendra Mishra serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U33110DL2007PTC169597
- Company No.
169597
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Oct 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Triodent Meditech India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Brajesh Mishra  | Director | 19-Oct-2007 | Current |
| Rajendra Mishra | Director | 10-Jan-2008 | Current |
Financial Performance of Triodent Meditech India.
Triodent Meditech India Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 18.75% decrease. The company also saw a slight improvement in profitability, with a 5.38% increase in profit. The company's net worth moved up by a moderate rise of 7.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Triodent Meditech India?
In 2020, Triodent Meditech India had a promoter holding of 70.00% and a public holding of 30.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.20 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.12 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Jul 2020 | Others | ₹0.20 M | Open |
| 07 Apr 2018 | Others | ₹1.00 M | Open |
How Many Employees Work at Triodent Meditech India?
Unlock and access historical data on people associated with Triodent Meditech India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Triodent Meditech India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Triodent Meditech India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
